AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 41.03 |
Market Cap | 6.51B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.09 |
PE Ratio (ttm) | -49.06 |
Forward PE | n/a |
Analyst | Buy |
Ask | 164.09 |
Volume | 1,241,830 |
Avg. Volume (20D) | 685,742 |
Open | 103.94 |
Previous Close | 103.36 |
Day's Range | 101.90 - 105.54 |
52-Week Range | 72.24 - 121.90 |
Beta | undefined |
About BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally avail...
Analyst Forecast
According to 18 analyst ratings, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $125, which is an increase of 21.92% from the latest price.
Next Earnings Release
Analysts project revenue of $145.32M, reflecting a 101.95% YoY growth and earnings per share of -0.7, making a -61.54% decrease YoY.
2 days ago · https://thefly.com
Blueprint Medicines price target lowered by $11 at Wedbush, here's whyBlueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%)
2 months ago · seekingalpha.com
Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology DrugsBlueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion int...
2 months ago · seekingalpha.com
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call TranscriptBlueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief E...